Esperion Appoints Craig Thompson to Board of Directors, Adds Strategic Insight.

Esperion has appointed Craig Thompson, CEO of Cerevance, to its Board of Directors. Thompson brings over 20 years of biopharmaceutical leadership experience. He will serve as an independent director, expanding Esperion's Board to eight members. Thompson's strategic insight and operational expertise will be valuable as Esperion continues to develop innovative cardiovascular and cardiometabolic drugs.

Esperion Therapeutics, Inc. (NASDAQ: ESPR) has appointed Craig Thompson, CEO of Cerevance, to its Board of Directors. Thompson brings over two decades of biopharmaceutical leadership experience, serving as an independent director and expanding Esperion's Board to eight members. His strategic insight and operational expertise will be valuable as Esperion continues to develop innovative cardiovascular and cardiometabolic drugs.

Thompson has a proven track record in advancing innovative therapies and has held various leadership roles at Pfizer Inc., Merck & Co., and other biotechnology companies. He has been the CEO of Cerevance since April 2022 and is also a member of the board of directors at NervGen Pharma Corp. Thompson's deep understanding of pharmaceutical commercialization and clinical development aligns with Esperion's mission to deliver life-saving solutions to patients worldwide.

"We are thrilled to welcome Craig to our Board of Directors," said Sheldon Koenig, President and CEO of Esperion. "With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug development."

Thompson, who holds a Bachelor of Commerce degree from McMaster University and an MBA from the University of Notre Dame, is excited to join Esperion. "I am honored to join the Board of Esperion, a company at the forefront of transforming cardiovascular disease prevention," he said. "With cardiovascular conditions remaining the leading cause of death globally, the need for innovative, proactive solutions has never been greater. I look forward to working alongside this exceptional team to help guide strategic decisions and accelerate the development of impactful, science-driven approaches that can improve and extend lives."

Esperion is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The company developed and is commercializing the only U.S. FDA-approved oral, once-daily, non-statin medicines for patients at risk for cardiovascular disease and struggling with elevated low-density lipoprotein cholesterol (LDL-C). Esperion continues to build on its success with its next-generation program, which is focused on developing ATP citrate lyase inhibitors (ACLYi).

References:
[1] https://www.marketscreener.com/quote/stock/ESPERION-THERAPEUTICS-INC-13479951/news/Esperion-Appoints-Craig-Thompson-to-Board-of-Directors-50389522/
[2] https://www.esperion.com/news-releases/news-release-details/esperion-appoints-craig-thompson-board-directors